-
-
-
-
-
-
-
Raymond James on Bristol-Myers Squibb Co. (BMY): 'we do not view the ZEPHYR data as signaling a risk to Cobenfy across indications'
-
-
-
-
-
-
-
MapLight Therapeutics (MPLT) PT Raised to $52 at UBS on Enhanced Sales Outlook
-
-
-
-
-
-
-
UBS Starts MapLight Therapeutics (MPLT) at Buy
-
-
-
-
-
-
-
MapLight Therapeutics gets FDA fast track status for Alzheimer's drug
-
-
-
-
-
-
-
MapLight Therapeutics IPO reportedly well oversubscribed
-
-
444,395 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

